Role Definition
| Field | Value |
|---|---|
| Job Title | Biostatistician |
| Seniority Level | Mid-Level |
| Primary Function | Designs and analyses clinical trials and epidemiological studies for pharmaceutical companies, CROs, and public health organisations. Develops Statistical Analysis Plans (SAPs), performs survival analysis, adaptive trial design, Bayesian methods, and causal inference under FDA/ICH-GCP regulatory frameworks. Produces tables, figures, and listings (TFLs) for regulatory submissions. Works primarily in SAS, R, and Python. |
| What This Role Is NOT | NOT a general statistician (broader scope, no FDA regulatory mandate). NOT a SAS programmer (executes code, does not design studies). NOT a data analyst (descriptive reporting). NOT a data scientist (ML model deployment). NOT a biostatistics director or principal biostatistician (owns departmental strategy and regulatory relationships). |
| Typical Experience | 3-7 years. MS or PhD in biostatistics, statistics, or epidemiology. Common credentials: ASA GStat/PStat. Median salary $105K-$127K (Coursera/Salary.com 2025-2026); pharma hubs $130K-$160K+. |
Seniority note: Entry-level biostatisticians executing pre-defined SAPs would score Yellow (~38-42). Senior/principal biostatisticians who own regulatory strategy, design adaptive trials, and serve as the qualified statistician on NDA/BLA submissions would score deeper Green (~55-60) — the accountability and regulatory authority layers provide stronger protection.
Protective Principles + AI Growth Correlation
| Principle | Score (0-3) | Rationale |
|---|---|---|
| Embodied Physicality | 0 | Fully digital, desk-based. All work in SAS/R/Python environments. |
| Deep Interpersonal Connection | 1 | Collaborates with clinical teams, medical monitors, and data managers. Professional/technical relationships matter but are not deeply personal. |
| Goal-Setting & Moral Judgment | 2 | Significant methodological judgment: choosing between frequentist and Bayesian approaches, designing adaptive trials, defining estimands (ICH E9 R1), selecting endpoints, and determining sample sizes. Defines "how should we measure treatment effect?" — a genuine goal-setting function. But works within protocol objectives set by clinical and medical teams. |
| Protective Total | 3/9 | |
| AI Growth Correlation | 0 | Neutral. AI creates new tasks (validating AI/ML models for FDA, interpreting AI-derived endpoints) but AutoML also compresses routine modelling. More clinical trials use AI-derived biomarkers, increasing complexity that demands biostatistical expertise, but routine TFL generation is being automated. Effects roughly cancel. |
Quick screen result: Protective 3 + Correlation 0 — likely Yellow or borderline Green. Proceed to quantify.
Task Decomposition (Agentic AI Scoring)
| Task | Time % | Score (1-5) | Weighted | Aug/Disp | Rationale |
|---|---|---|---|---|---|
| Clinical trial design & protocol stats sections | 20% | 2 | 0.40 | AUGMENTATION | Designing RCTs, adaptive trials, determining sample sizes, selecting endpoints, defining estimands. Requires deep understanding of regulatory requirements, clinical context, and methodological trade-offs. AI can suggest designs but cannot own the judgment of what is appropriate for this specific trial and patient population. |
| SAP development | 15% | 2 | 0.30 | AUGMENTATION | Writing the Statistical Analysis Plan — the binding document that defines every analysis before unblinding. Requires anticipating regulatory questions, choosing sensitivity analyses, and defending methodology. AI drafts sections but the human biostatistician decides the analytical strategy. |
| Statistical modelling & analysis | 20% | 3 | 0.60 | AUGMENTATION | Survival analysis (Cox, Kaplan-Meier), mixed models, Bayesian adaptive analysis, subgroup analyses. AutoML handles standard models; custom clinical trial analyses (MMRM, ANCOVA with specific covariate structures) require human specification. AI accelerates execution but the biostatistician validates assumptions and diagnostics. |
| Data cleaning & validation (CDISC/SDTM/ADaM) | 10% | 4 | 0.40 | DISPLACEMENT | Transforming raw data into CDISC-compliant datasets, handling missing data, creating derived variables. AI/automation tools handle this end-to-end for standard structures. Domain-specific edge cases and protocol deviations keep this at 4 not 5. |
| Results interpretation & clinical significance | 15% | 2 | 0.30 | AUGMENTATION | Determining clinical (not just statistical) significance, identifying confounders, assessing treatment effect heterogeneity, making recommendations on study success/failure. Requires clinical domain knowledge and judgment AI cannot reliably provide. |
| Regulatory submission support | 10% | 2 | 0.20 | AUGMENTATION | Writing CSR statistics sections, responding to FDA/EMA queries, defending analytical choices to regulators. Requires understanding regulatory expectations and precedent. AI drafts but the biostatistician owns the content and bears accountability. |
| Cross-functional collaboration | 10% | 2 | 0.20 | AUGMENTATION | Working with clinical, medical, data management, and programming teams. Translating clinical questions into statistical frameworks. Explaining results to non-statisticians. Requires organisational context and professional judgment. |
| Total | 100% | 2.40 |
Task Resistance Score: 6.00 - 2.40 = 3.60/5.0
Displacement/Augmentation split: 10% displacement, 90% augmentation, 0% not involved.
Reinstatement check (Acemoglu): Moderate-to-strong. AI creates new tasks: validating AI/ML-derived endpoints for regulatory submissions, designing statistical frameworks for AI-augmented adaptive trials, auditing algorithmic patient stratification, and interpreting real-world evidence from AI-curated data sources. The "statistical auditor of AI in clinical research" is a genuine emerging function, partially offsetting automation of routine TFL generation.
Evidence Score
| Dimension | Score (-2 to 2) | Evidence |
|---|---|---|
| Job Posting Trends | +1 | BLS projects 8% growth 2024-2034 for statisticians broadly. Coursera cites 11% through 2033 for biostatisticians specifically. Clinical trial volume increasing globally (ClinicalTrials.gov active studies growing). CRO demand strong. Pharma R&D investment >$3B on AI alone. |
| Company Actions | 0 | No pharma companies or CROs cutting biostatisticians citing AI. Teams maintaining or growing for regulatory submissions. Biopharma layoffs ~42,700 in 2025 were business-cycle driven (patent cliffs, restructuring), not AI displacement. FDA regulatory mandate ensures continued demand. |
| Wage Trends | +1 | Median $105K-$127K (Coursera/Salary.com 2026) growing above inflation. Pharma hubs (Boston, SF, RTP) $130K-$160K+. Premium emerging for AI/ML-fluent biostatisticians and adaptive trial specialists. ZipRecruiter clinical biostatistician average $122K. Above-inflation growth. |
| AI Tool Maturity | 0 | AutoML (H2O, DataRobot), SAS Viya AI features, and R/Python automation augment routine analysis. AI tools handle standard TFL generation and data cleaning. But core tasks — trial design, SAP strategy, regulatory defence — have no viable autonomous AI alternative. FDA will not accept AI-only statistical analysis. Anthropic observed exposure 21.07% — predominantly augmented, not automated. |
| Expert Consensus | +1 | Consensus: transformation not displacement. Deloitte, McKinsey: AI augments pharma R&D, does not replace qualified statisticians. FDA's evolving AI/ML guidance explicitly requires human statistical oversight. ICH E9 R1 (estimands framework) increases methodological complexity, requiring more sophisticated biostatistical judgment. |
| Total | +3 |
Barrier Assessment
Reframed question: What prevents AI execution even when programmatically possible?
| Barrier | Score (0-2) | Rationale |
|---|---|---|
| Regulatory/Licensing | 2 | FDA requires a "qualified statistician" for NDA/BLA submissions. ICH-GCP mandates human statistical oversight in clinical trials. IRB requires human accountability for study design. EU Clinical Trials Regulation mandates human statistician sign-off. No regulatory pathway for AI-only statistical analysis in drug development. This is the key differentiator from general statisticians. |
| Physical Presence | 0 | Fully remote/digital. No physical barrier. |
| Union/Collective Bargaining | 0 | No union representation. At-will employment in pharma/CRO sector. |
| Liability/Accountability | 1 | Statistical errors in clinical trials have patient safety consequences. FDA holds sponsors accountable for statistical integrity. Drug recalls, failed submissions, and patient harm trace back to statistical methodology. Organisational liability is significant; personal liability is rare but possible in egregious cases. |
| Cultural/Ethical | 1 | FDA and EMA reviewers expect to engage with human biostatisticians during submissions and advisory committees. Clinical community insists on human oversight for patient safety. Regulatory agencies will not accept AI-generated statistical justifications without human sign-off. |
| Total | 4/10 |
AI Growth Correlation Check
Confirmed at 0 (Neutral). AI growth creates countervailing forces: more AI/ML-derived endpoints and biomarkers in clinical trials increase demand for biostatisticians who can design studies around them. RWE from AI-curated data sources requires biostatistical methodology. But AutoML and AI-powered TFL generation reduce headcount for routine execution work. The net effect is approximately neutral. This is NOT an accelerated role — biostatisticians do not exist because of AI — but unlike general statisticians, the clinical trial regulatory mandate provides a demand floor independent of AI adoption.
JobZone Composite Score (AIJRI)
| Input | Value |
|---|---|
| Task Resistance Score | 3.60/5.0 |
| Evidence Modifier | 1.0 + (3 × 0.04) = 1.12 |
| Barrier Modifier | 1.0 + (4 × 0.02) = 1.08 |
| Growth Modifier | 1.0 + (0 × 0.05) = 1.00 |
Raw: 3.60 × 1.12 × 1.08 × 1.00 = 4.3546
JobZone Score: (4.3546 - 0.54) / 7.93 × 100 = 48.1/100
Zone: GREEN (Green ≥48, Yellow 25-47, Red <25)
Sub-Label Determination
| Metric | Value |
|---|---|
| % of task time scoring 3+ | 30% |
| AI Growth Correlation | 0 |
| Sub-label | Green (Transforming) — 30% ≥ 20% threshold, Growth ≠ 2 |
Assessor override: None — formula score accepted. 48.1 is borderline (0.1 points above Yellow) but the score is honest. The FDA regulatory barrier (4/10 vs general statistician's 1/10) is the decisive differentiator. Removing barriers entirely would yield ~44.0 (Yellow Urgent), confirming the classification is barrier-dependent. The score calibrates correctly: above Statistician (34.6), nearly identical to Epidemiologist (48.6), below Actuary (51.1) and Medical Scientist (54.5).
Assessor Commentary
Score vs Reality Check
The 48.1 Green (Transforming) is barrier-dependent and borderline. Stripping the regulatory barrier (setting barriers to 0) would yield ~44.0 — Yellow Urgent. This is flagged explicitly: the classification rests on FDA/ICH-GCP mandating a human qualified statistician. If regulatory agencies ever accept AI-only statistical analysis for drug approvals, the score collapses to Yellow. That scenario is implausible in the 5-year assessment horizon — FDA's 2025-2026 AI/ML guidance moves in the opposite direction, requiring more human oversight, not less. The score sits 0.1 points above the zone boundary but the underlying logic is sound: the biostatistician has meaningfully stronger task resistance (3.60 vs 3.35) and dramatically stronger barriers (4 vs 1) than the general statistician.
What the Numbers Don't Capture
- Bimodal distribution within the subspecialty. "Biostatistician" spans regulatory biostatisticians leading NDA submissions (would score ~55+) to CRO-based biostatisticians running standardised analyses across multiple trials (would score ~42-45, Yellow). The mid-level assessment averages across these sub-populations.
- SAS programmer vs biostatistician title conflation. Many CROs use "biostatistician" for roles that are functionally SAS programming — executing pre-written SAPs rather than designing them. These would score significantly lower (~35-38, Yellow Urgent).
- AutoML compression of the middle tier. Like general statisticians, fewer biostatisticians can handle more trials with AI augmentation. Headcount compression without job elimination is the trajectory — teams of eight become five.
- Regulatory barrier strengthening, not weakening. ICH E9 R1 (estimands framework), adopted 2021, increases methodological complexity and human judgment requirements. The barrier is getting stronger, not eroding.
Who Should Worry (and Who Shouldn't)
If you design clinical trials, develop SAPs, select methodology for adaptive designs, and defend statistical strategy to FDA reviewers — you are significantly safer than the borderline Green label suggests. Regulatory accountability and methodological judgment are irreducibly human in the current framework. The senior biostatistician who owns the regulatory relationship is firmly Green.
If you primarily execute pre-written SAPs, generate standard TFLs, and validate SAS outputs across multiple CRO projects — you are closer to Yellow than Green. This execution layer is where AutoML and AI-powered SAS tools compress headcount fastest. The CRO biostatistician whose value is "I can run PROC MIXED" is competing against tools that do this faster.
The single biggest separator: whether you design the statistical strategy or execute it. Design is protected by regulatory mandate. Execution is being automated.
What This Means
The role in 2028: The surviving mid-level biostatistician spends less time on TFL generation and data cleaning (automated) and more time on adaptive trial design, estimand framework implementation, real-world evidence methodology, and validating AI-derived endpoints. The role becomes more strategic and less computational. Headcount contracts 15-25% as AI augmentation raises per-person throughput, but the regulatory mandate ensures a floor — every NDA/BLA still requires a qualified statistician.
Survival strategy:
- Own the regulatory methodology. Become the person who designs adaptive trials, defines estimands, and defends statistical choices to FDA reviewers. ICH E9 R1 expertise is the moat.
- Master AI/ML validation for clinical research. Learn to evaluate AI-derived endpoints, validate ML-based patient stratification, and design studies for AI-augmented therapeutics. This is genuine new work.
- Specialise in complex trial designs. Bayesian adaptive trials, basket/umbrella/platform designs, and RWE integration require sophisticated methodology that AutoML cannot replicate.
Timeline: 3-5 years for significant role transformation. Regulatory mandates ensure the role persists, but the daily work shifts substantially toward design and strategy. CRO execution roles compress first; pharma regulatory roles transform last.
